Tillkännagivande • Sep 03
IR-Med Inc. announced that it has received $0.064754 million in funding On September 2, 2025, IR-Med Inc. closed the transaction. Tillkännagivande • Jun 11
IR-Med Inc. announced that it has received $0.088678 million in funding On June 9, 2025, IR-Med Inc closed the transaction. Tillkännagivande • May 03
IR-Med Inc. has withdrawn its IPO in the amount of $8 million. IR-Med Inc. has withdrawn its IPO in the amount of $8 million.
Security Name: Unit
Security Type: Equity/Derivative Unit
Transaction Features: New Market Listing Tillkännagivande • Apr 11
IR-Med, Inc. Receives Advance Payment from the Israeli Innovation Authority On April 6, 2025, IR-Med Inc. received an amount of ILS 644,551 (approximately $171,468), as an advance payment from the Israeli Innovation Authority (the “IIA”) to fund the development of a device for the assessment of diabetic foot ulcers before skin breakage among diabetic patients. The IIA awarded the Company a total amount of ILS 4,603,938 (approximately $1,222,786), which includes a grant of 40% or ILS 1,841,575 (approximately $489,035). The IIA award will be distributed in tranches based on specific milestones and the progress of the product development, from January 1, 2025 to December 31, 2025. The approval of the research and development project by the IIA is subject to the provisions of the Encouragement of Industrial Research and Development Law, 5744-1984 (the “Innovation Law”), as well as the rules, procedures, and guidelines established by the IIA. Pursuant to the terms of the grant, the Company is required to comply with all applicable regulatory and reporting obligations, including limitations relating to intellectual property and changes in ownership or control. In addition, the Company is obligated to pay royalties to the IAA for revenues generated in connection with the approved project, in accordance with the terms set forth in the grant approval and the Innovation Law. Tillkännagivande • Apr 02
IR-Med Inc. announced delayed annual 10-K filing On 03/31/2025, IR-Med Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Tillkännagivande • Aug 28
IR-Med Inc. Announces Chief Executive Officer Changes IR-MED Inc. announced that Mr. Ran Ziskind has joined the Company as Chief Executive Officer (CEO), effective September 1, 2024. Mr. Ronnie Klein, who had been serving as Interim CEO, continues to serve as the Company’s Chief Technology Officer. Mr. Ziskind is a highly experienced high-tech innovator and company leader with two decades of expertise in launching, developing, and expanding pioneering enterprises that were later acquired by leading firms in their fields. Throughout his career, Mr. Ziskind has been instrumental in the success of numerous companies playing a key role in every stage of the business value chain, from ideas, to IP portfolio management, to development, manufacturing, and commercialization of products that have become established industry standards. Mr. Ziskind was co-founder and CEO of Galatea Ltd., a groundbreaking startup in diamond manufacturing from 2004 to 2023. Under his leadership, Galatea developed a pioneering electro-optics technology that became the industry gold standard, driving significant innovations in the field. His role encompassed a broad range of responsibilities, including spearheading research and development, managing intellectual property with a global patent portfolio, defining product specifications, and leading the company through challenging global conditions, including the 2007-2008 financial crisis, ultimately resulting in its acquisition by Sarin Technologies, the world’s leading company in the field. Prior to this, Mr. Ziskind was an engineer at Lithotech Ltd., where he contributed to the development of medical technologies, and at Eurika Ltd., where he worked on various engineering projects. Mr. Ziskind has dual degrees in mechanical engineering and management from Tzur University. Tillkännagivande • Jul 15
IR-Med Inc. Receives $500,000 Grant from the Israel Innovation Authority to Develop its Platform Technology for the Early Detection of Diabetic Foot Ulcers IR-MED Inc. announced it has received a grant from the Israel Innovation Authority (IIA) in the amount of approximately $500,000, to develop its platform technology for a new indication, a decision support device for the early detection of diabetic foot ulcers. The grant’s 13-month development timeline is proceeding on schedule with IR-MED having achieved its mid-point milestones. Computer simulations of infrared light reflectance from lesions under the skin surface have been completed, and based on these data, the Company is building the DiaSafe™ device’s hardware in accordance with the development plan agreed upon with the IIA. By sensing the invisible, DiaSafe™, IR-MED’s newest handheld device, is being designed to non-invasively analyze the biomarkers of blood and tissue, at the point of care, to help healthcare providers prevent diabetic foot ulcers from developing in their diabetic patients. The Company believes an effective early detection device can reduce healthcare costs, save limbs, and save lives. Diabetic foot ulcers are more cost effective to manage in their initial stages. Detecting and treating diabetic foot ulcers early can significantly improve quality of life by reducing pain and increasing mobility. Early intervention can reduce death rate associated with diabetic foot complications. Diabetic foot ulcers are a major cause of preventable death for people with diabetes, according to an article published in Diabetes Care, the journal of the American Diabetes Association. An estimated 537 million people globally have diabetes, and 19% to 34% of these, or up to 183 million people, will develop a diabetic foot ulcer during their lifetime. Of these, 20%, or up to 37 million people, will require lower-extremity amputation, and 10%, or 18 million people, will die within one year of their first diabetic foot ulcer diagnosis. IR-MED’s DiaSafe™ is based on the same platform technology as the Company’s lead device, PressureSafe™, a decision support device for the early detection of pressure injuries, which is expected to launch in the U.S. in the second half of 2024. Tillkännagivande • Jun 25
IR-Med Inc. has filed an IPO in the amount of $8 million. IR-Med Inc. has filed an IPO in the amount of $8 million.
Security Name: Unit
Security Type: Equity/Derivative Unit
Transaction Features: New Market Listing Tillkännagivande • Jun 13
IR-Med Inc. Appoints Avital Rosenberg as A Class I Director and Member of the Audit Committee IR-Med Inc. announced on June 4, 2024, the board of directors (the “Board”) of the Company, appointed Ms. Avital Rosenberg to serve as a Class I director and a member of the Board’s Audit Committee, to fill an existing vacancy on the Board, effective immediately. Ms. Rosenberg will serve until her earlier removal or resignation. The Board determined that Ms. Rosenberg is an independent director as defined under Rule 10A-3 under the Securities Exchange Act of 1934, as amended. Ms. Avital Rosenberg, age 49, is an international business-oriented counsel and an Israeli licensed attorney with over 20 years of extensive experience in ESG, Compliance, M&A, Securities, and complex business development international transactions. Ms. Rosenberg currently serves as the Executive Vice President and Chief Legal Officer at Rafael Advanced Defense Systems Ltd. (“Rafael”), a position she has held since 2019. In this role, she is responsible for all legal affairs, compliance, and regulatory activities of the Rafael Group worldwide. Ms. Rosenberg is also a member of Rafael’s Corporate Senior Management, General Counsel of the board of directors, and head of the legal department since 2019. Ms. Rosenberg served as Deputy Chief Legal Officer and Head of the Business Development & International Transactions Unit at Rafael, from 2008 to 2019, leading M&A transactions in over 12 countries and specializing in the U.S. market. She also held the role of Corporate Secretary or board member in a few of Rafael’s subsidiaries, and managed major international defense transactions and public financing activities. Ms. Rosenberg received her LL.M in Commercial Law and her Executive MBA from Bar-Ilan University. Tillkännagivande • May 24
IR-Med Inc.’s PressureSafe Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel’s Hmo IR-MED Inc., published a poster presentation on its website titled “Near Infra-Red Spectroscopy scanner for early detection of stage 1 pressure injury and deep tissue injury – clinical study results”, which includes data that was presented at the National Pressure Injury Advisory Panel (NPIAP) 2024 Annual Conference in San Antonio, Texas. The poster was also recently shared by Clalit Innovation, which described PressureSafe as a “Breakthrough in pressure ulcer diagnosis…” and “Truly impact of an innovative tool!”. PressureSafe is a decision support device that has received U.S. Food and Drug Administration (FDA) listing confirmation for the indication of pressure injuries. PressureSafe uses infra-red spectroscopy combined with an AI-based algorithm for the early, non-invasive, and skin color agnostic detection of pressure injuries with real-time analysis at the point of care. IR-MED conducted a usability study in conjunction with two medical centers owned by Clalit, the world’s second largest health maintenance organization (HMO) and the largest HMO in Israel. A total of 924 scans were conducted on 154 body locations. Nurses conducting the scans did not see the PressureSafe’s results in real time as the results were coded to. PressureSafe detected Stage 1 /suspected deep tissue injury (sDTI) pressure injuries with 92% sensitivity and 88% specificity. During the study period, the incidences of pressure injuries were reduced by 50% in comparison to the levels prior to the study. In the U.S. alone, 60,000 patients die every year as a direct result of pressure injuries. Patient care costs per pressure injury ranges from $20,900 up to $151,700, for the 2.5 million patients per year who develop pressure injuries. Pressure injuries are one of the five most common harms experienced by patients and the second most common claim for lawsuits after wrongful death. Tillkännagivande • Apr 05
IR-Med Inc.'S PressureSafe Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries IR-Med Inc. announced its PressureSafe decision support device has received U.S. Food and Drug Administration (FDA) listing or the indication of pressure injuries. PressureSafe is classified as a Class I device and is exempt from 510(k) premarket submission. PressureSafe uses infra-red spectroscopy combined with an AI-based algorithm for the early, non-invasive, and skin color agnostic detection of pressure injuries with real-time analysis at the point of care. PressureSafe achieved 92% efficacy in the early, non-invasive detection of pressure injuries, regardless of skin color, in a study conducted in Israel with the world’s second largest HMO, Clalit. Nearly 1,500 scans were performed on 154 body locations. In the U.S. alone, 60,000 patients die every year as a direct result of pressure injuries. Patient care cost per pressure injury ranges from $20,900 up to $151,700, for the 2.5 million patients per year who develop pressure injuries. Pressure injuries are one of the five most common harms experienced by patients and the second most common claim for lawsuits after wrongful death. Tillkännagivande • Feb 13
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16 IR-Med Inc. announced that final data from a study conducted at two medical centers, Beit Rivka Hospital, and Rabin Medical Center, both in Petah Tikva and owned by Clalit, the world’s second health maintenance organization (HMO) and the in Israel, will be presented at the National Pressure Injury Advisory Panel(NPIAP) 2024 Annual Conference which will take place in San Antonio, Texas on February 16-17, 2024. The single arm, bi-center, open label, safety and efficacy study evaluated PressureSafe™, IR-MED’s decision support device, which uses infra-red spectroscopy combined with an AI-based algorithm to diagnose Stage 1 pressure injuries, compared to standard of care visual and tactile inspection. IR-MED’s clinical and execute team will demonstrate PressureSafe at booth #102 at NPIAP 2024, which is attended by the world’s top thought leaders and practitioners in the prevention and treatment of pressure injuries. Tillkännagivande • Oct 17
IR-Med Inc., Annual General Meeting, Nov 07, 2023 IR-Med Inc., Annual General Meeting, Nov 07, 2023, at 09:00 US Eastern Standard Time. Location: offices of Sullivan & Worcester LLP, located at 1633 Broadway, New York, NY 10019 New york New York United States Agenda: To elect three Class II directors to serve a three-year term expiring in 2026; to approve an amendment to the Articles of Incorporation of the Company to increase the number of authorized Common Shares from two hundred and fifty million (250,000,000) shares, par value $0.001 per share, to six hundred million (600,000,000) shares, par value $0.001 per share; to approve of an amendment to the Company’s 2020 Incentive Stock Plan to increase the number of shares available thereunder from 16,000,000 to 17,500,000 shares; to ratify the appointment of Somekh Chaikin Member Firm of KPMG International as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023; and to transact other business. Tillkännagivande • Oct 05
IR-MED Announces Executive Changes Effective as of October 15, 2023 IR-MED appointed Healthcare Executive and Entrepreneur Tzur Di-Cori as Chief Executive Officer, effective as of October 15, 2023. Oded Bashan, who serves as Chairman of the Board and Interim CEO, will continue as the Company’s Chairman. Mr. Di-Cori brings to IR-MED more than 30 years of experience in executive positions at several successful medical device and high-tech companies. A talented entrepreneur with exceptional team building capabilities and leadership skills, Mr. Di-Cori is return-on-investment oriented and an expert in building and executing business strategy. His vast experience in the healthcare sector spans companies from start-up to large multinational organizations, in roles ranging from Founder to President and CEO. Mr. Di-Cori, Co-Founder and owner at NatureIM Ltd. Since 2023, a private holding company focused on developing peptide-derived materials for various purposes. From 2020-2023, Mr. Di-Cori served as CEO of DUSMIT Ltd., a privately–owned start-up company active in the health tech industry and agriculture which focuses on the development of air purification technology based on a real-time denaturation process, solving indoor air pollution. From 2017-2020, he served as Chief Executive Officer and co-founder at Veoli Ltd., a company which develops solutions for medical cannabis delivery. Prior to that, from 2014 to 2017, he served as Chief Executive Officer of Motorika Medical Ltd., a company developing robotic physical therapy devices for upper and lower extremities. From 2011 to 2014 Mr. Di-Cori served as President and CEO at LifeWatch Technologies Ltd., which was subsequently acquired and is currently owned by Koninklijke Philips N.V. Tillkännagivande • Sep 28
Ir-Med to Conduct Usability Study with Methodist Healthcare of San Antonio for Its Pressuresafe Device Which Is Slated for U.S. Launch in H1 2024 IR-MED Inc. announced it has signed a Clinical Trial Agreement with the Methodist Healthcare System of San Antonio to conduct a useability study titled “Safety and Efficacy of the PressureSafe Device for Early Detection of Pressure Injury in People with Various Skin Tones, Including Dark Skin Tones.” Methodist Healthcare is recognized as the most respected healthcare provider in its region. With a network of 85 hospitals, 9 of which are acute care facilities, Methodist Healthcare employs more than 11,000 people, including 2,700 physicians. Approximately 50% of subjects recruited for the upcoming study will have dark skin tone, thus producing comparative data on PressureSafe’s accuracy as a decision support device in detecting early-stage pressure injuries in people of darker and lighter skin tones. While early stage pressure injuries can be more difficult to see on dark skin tones, the current standard of care for the detection of pressure injuries is visual skin inspection. Research shows that people with dark skin tones suffer from pressure injury at more than twice the rate of those with lighter skin tones, as characterized by higher pressure injury rates, higher risks of mortality from pressure injuries, and more severe pressure injuries. According to a study published in September 2023 in Advances in Skin & Wound Care, among all racial and ethnic groups in the U.S., black patients had the highest prevalence of the most severe pressure injuries while white patients had the lowest. The peer-reviewed study goes on to state that due to increasing racial diversity in the U.S., including persons of mixed ethnic and racial backgrounds, there is an urgent need for improved techniques to identify and treat developing pressure injuries earlier. In the U.S. alone, 60,000 patients die every year as a direct result of pressure injuries. Patient care cost per pressure injury ranges from $20,900 up to $151,700, for the 2.5 million patients per year who develop pressure injuries. Pressure injuries are one of the five most common harms experienced by patients and the second most common claim for lawsuits after wrongful death. IR-MED’s prior usability study for PressureSafe was conducted at two hospitals in Israel owned by Clalit, the world’s second largest health maintenance organization (HMO). Interim results demonstrate PressureSafe detected pressure injuries with 96% sensitivity and 91% specificity. Final results are expected by the end of 2023. Tillkännagivande • Sep 14
IR-Med Inc. Appoints Richard Serbin, Esq. to Its Advisory Board IR-Med Inc. announced the appointment of Richard Serbin, Esq. to its Advisory Board as the Company prepares to file for regulatory listing of its PressureSafe™ device with the U.S. Food & Drug Administration (FDA) with the intent of a subsequent market launch in the U.S. Mr. Serbin was the Chief FDA Counsel for Revlon Corporation and Johnson & Johnson Corporation. He held senior management roles at Johnson & Johnson and served on the Board of Directors of numerous Johnson & Johnson subsidiary companies including Ethicon, Ortho, Johnson & Johnson Consumer Products, Pittman-Moore, McNeil and Johnson & Johnson Development Corporation, that company’s strategic venture capital division. His broader experience includes serving on the boards of numerous other companies involved in biotechnology, dermatology, veterinary medicine, female healthcare, medical devices, photodynamic therapy, surgical and consumer products. For more than a decade, Mr. Serbin has served as a Senior Advisor to the Swedish American Life Science Summit (SALSS), the leading invitation healthcare summit, held annually in Stockholm, Sweden. Currently, he is Managing Director of Platform Health Ventures, a healthcare strategic and tactical consulting group. He formerly served as Chief Operating Officer of the Gorlin Companies and he served as President of Bradley Pharmaceuticals. He has a Bachelor of Science and a Bachelor of Pharmacy from Rutgers University and Rutgers University College of Pharmacy, a J.D. degree from Seton Hall Law School, and a Master’s Degree in Trade Regulations and Law from New York University Law School. Tillkännagivande • Jul 18
Ir-Med Inc. Announces Interim Results from A Clinical Study of Pressuresafe IR-MED Inc. announced topline interim results from a clinical study of PressureSafe, a noninvasive handheld optical monitoring device that supports early detection of pressure injuries (PI) to the skin and underlying tissue. PressureSafe demonstrated very high efficacy in noninvasively detecting the presence and absence of pressure injuries below the skin's surface. These data confirm that PressureSafe can augment visual inspection with very high accuracy while bringing the added benefits of automated cloud-based digital storage of scan results, saving time and contributing to the healthcare provider's data-driven decision making. Moreover, because PressureSafe is detecting biomarkers below the skin's surface, it can be more effective at sensing pressure injuries that are not yet visible to the human eye, leading to better outcomes for patients, especially those with darker skin tones. PressureSafe is a handheld device to support early detection of pressure injuries to the skin and underlying tissue, regardless of skin tone. $26.8 billion is spent each year to prevent and treat pressure injuries that result from long-term pressure on hard surfaces such as wheelchairs and beds. Tillkännagivande • Jun 08
IR-Med Inc. Appoints Lynn Eschenbacher to its Advisory Board IR-MED Inc. announced the appointment of Lynn Eschenbacher PharmD, MBA, FASHP, CPEL to its Advisory Board. Dr. Eschenbacher is an innovative business development executive with extensive experience in the healthcare industry. As CEO and Founder of Echelon Health Strategies, she develops and delivers innovative strategies, operational excellence, and relationship networking to drive growth resulting in positive business outcomes and profitability. Focused on addressing access, adherence, and affordability across the continuum of healthcare, Dr. Eschenbacher works to ensure equity. She addresses impactful issues by engaging with Boards of Pharmacy, professional organizations, and the U.S. Congress. Dr. Eschenbacher serves as Venture Partner at SpringTide, a healthcare focused venture capital firm, Chief Customer Officer at RxLive, Strategic Advisory Board Member at Atlas Health, as well as several other key roles with innovative healthcare companies. Among Dr. Eschenbacher’s many accomplishments, she held the position of the Chief Pharmacy Officer and Vice President Medication Management at Ascension Healthcare. Dr. Eschenbacher also held a number of positions including Medication Safety Officer at Duke University Health System. She earned her doctor of pharmacy from The University of Texas at Austin, an MBA from Duke University, and a BS in Biology from Indiana University. As an Advisory Board member at IR-MED, Dr. Eschenbacher will advise on the development and strategic market launch of the Company’s lead product, PressureSafe, which uses penetrating infrared light to ‘look’ beneath the skin’s surface, senses biomarkers and structural changes in tissue layers for the early detection of pressure injuries. The Company plans to file for regulatory approval of PressureSafe with the U.S. Food and Drug Administration in fourth quarter of 2023, with commercial launch soon to follow, pending approval. Tillkännagivande • Nov 29
IR-Med Inc., Annual General Meeting, Dec 12, 2022 IR-Med Inc., Annual General Meeting, Dec 12, 2022, at 09:00 US Eastern Standard Time. Location: offices of Aboudi Legal Group, PLLC, 5th Floor, 745 Fifth Avenue New York United States Agenda: To elect two Class I directors to serve a three-year term expiring in 2025; to approve of an amendment to the Company’s 2020 Equity plan to increase the number of shares available thereunder; to ratify the appointment of Somekh Chaikin Member Firm of KPMG International as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022; to approve, in a non-binding advisory vote, the compensation of the Company’s named executive officers; to determine, in a non-binding advisory vote, the desired frequency of future non-binding advisory votes on the compensation of our named executive officers every year, every two years or every three years; and to consider and take action upon such other matters as may properly come before the meeting or any adjournment thereof. Tillkännagivande • May 12
IR-Med Announces Appointment of Moshe Gerber as Chief Executive Officer IR-Med announced the appointment of Moshe Gerber as Chief Executive Officer, effective immediately. Mr. Gerber brings more than 25 years’ experience in international business development, sales and operations across high-tech industries, including Artificial Intelligence (AI), software and medical devices, with wide ranging experience in product strategy and market analysis, of which 10 years’ experience was in leading roles at several companies in the medical devices industry. Gerber then served as VP Business Development and Sales at Mennen Medical, managing business development, marketing and sales activities through direct sales force and distributors worldwide. Tillkännagivande • Sep 04
International Display Advertising, Inc. announced that it expects to receive $5 million in funding International Display Advertising, Inc. (OTCPK:IDAD) announced a private placement for gross proceeds of minimum $1,800,000 to maximum gross proceeds of $5,000,000 on September 3, 2020. 
